Skip to main content
. 2020 Feb;32(1):115–128. doi: 10.21147/j.issn.1000-9604.2020.01.13

2. Ongoing clinical trials of immune checkpoint inhibitors in SCLC.

Clinical trial gov. identifier Phase Treatment arms Population Primary endpoint Primary completion
*, Number of participants experiencing dose-limiting toxicities; SCLC, small cell lung cancer; ED-SCLC, extensive stage small cell lung cancer; LD-SCLC, limited disease small cell lung cancer; PFS, progression-free survival; OS, overall survival; DLT, dose-limiting toxicity; AE, adverse effect; DCR, disease control rate; ORR, objective response rate.
First-line
 REACTION/
 NCT02580994
II Pembrolizumab+chemotherapy vs.
chemotherapy
ED-SCLC PFS August 2020
 CASPIAN/
 NCT03043872
III Durvalumab+tremelimumab+
chemotherapy vs.
Durvalumab+chemotherapy vs. chemotherapy
ED-SCLC OS September 30, 2019
 STIMULI/
 NCT02046733
II chemotherapy followed by nivolumab+ipilimumab vs. chemotherapy LD-SCLC OS, PFS October 2019
 KEYNOTE-604/
 NCT03066778
III Pembrolizumab+chemotherapy vs. Placebo+chemotherapy SCLC PFS, OS December 16, 2019
 KEYNOTE-011/
 NCT01840579
I Pembrolizumab vs. pembrolizumab+chemotherapy vs. Pembrolizumab+Ipilimumab vs. Pembrolizumab+chemotherapy+G-CSF Solid tumor, SCLC, NSCLC DLTs*, AE June 30, 2020
Second-line and beyond
 CheckMate-331/
 NCT02481830
I/II Nivolumab vs. chemotherapy topotecan vs. chemotherapy amrubicin Lung cancer OS August 17, 2018
 AFT-17/
 NCT02963090
II Pembrolizumab vs. topotecan SCLC PFS May 20, 2019
 MEDIOLA/
 NCT02734004
I/II MEDI4736 (anti-PD-L1 antibody) +Olaparib (PARP inhibitor) Ovarian, breast, SCLC, gastric cancers DCR, safety
and tolerability
August 5, 2022
 CA001-030/
 NCT02247349
II BMS-986012 (anti-fucosyl-GM1) vs. BMS-986012+nivolumab SCLC AE October 24, 2019
 NCT02701400 II Tremelimumab+durvalumab vs. Tremelimumab+durvalumab+radiation Relapsed SCLC PFS, ORR January 2020
Maintance treatment
 CheckMate-451 III Nivolumab vs. Nivolumab+ipilimumab vs. placebo Lung cancer OS, PFS October 1, 2018